Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Marco Zezza¹, Christophe Kosinski¹, Carine Mekoguem¹, Laura Marino¹, Haithem Chtioui², Nelly Pitteloud¹ and Faiza Lamine¹

Abstract

Background: The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) cause a broad spectrum of autoimmune adverse events. ICI-induced type 1 diabetes mellitus (T1DM) is extremely rare (< 1%) but potentially life-threatening. It appears to be more common with PD-1 blockade (or combination immunotherapy) than with anti-CTLA-4 therapy, often during the first three to six months of therapy.

Cases presentation: We report an acute onset T1DM with severe inaugural diabetic ketoacidosis (DKA) and remarkably elevated Glutamic Acid Decarboxylase antibody (GADA) titres following a single administration of combined ICI therapy with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in two adult patients with advanced metastatic melanoma. In these cases, the time to diabetes onset was remarkably short (two and five weeks), and one presented with fulminous T1DM in a previous long-standing type 2 diabetes mellitus.

Conclusions: Oncological patients treated with combination therapy of anti-PD-1 and anti-CTLA-4 can develop a particular pattern of T1DM, with very rapid onset within a few weeks after starting ICI therapy, even in the presence of an existing type 2 diabetes. ICI-induced T1DM is a medical emergency in presence of severe inaugural DKA and requires a collaboration between specialists and primary care physicians, as well as patient education, for early diagnosis and supportive care.

Keywords: Immune checkpoint inhibitor, Autoimmune adverse events, Endocrinopathies, Type 1 diabetes

Background

Immune checkpoint inhibitors (ICI) are the major breakthrough in cancer therapy in the last decade. Administration of monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (PD-L1) enhances the immune system response against tumour cells. ICI improve survival in a subset of cancer patients [1–4]. Nevertheless, ICI are frequently associated with immune-related adverse events (irAE) [5], and the combination of anti-CTLA-4 and anti-PD-1 or PD-L1 rises both the intensity and frequency rates of irAE up to 60% corresponding to a two or three-fold increase compared to single-agent ICI therapy [6]. ICI-induced irAE affect all organs, but gastrointestinal tract, liver, skin and endocrine systems are more often affected [5]. The most common ICI-associated endocrinopathies are thyroid disorders and hypophysitis [7]. ICI-induced type 1 diabetes mellitus (T1DM) is...
uncommon, with a reported frequency ranging from 0.2% in randomised clinical studies [7] to 0.9% in real-life setting [8].

We describe herein two patients with metastatic melanoma presenting with severe diabetic ketoacidosis (DKA) and positive β-cell autoantibodies shortly after a single infusion of ICI combination therapy with ipilimumab (IPI) and nivolumab (NIVO). Interestingly in the first case, we observed an acute onset of T1DM in a long-standing type 2 diabetes mellitus (T2DM) concurrently to immune-checkpoint inhibitor-induced pancreatic injury.

Cases presentation

Case 1

A 60-year-old man with a 10 years history of T2DM was diagnosed with a metastatic cutaneous melanoma and was started on ICI treatment, with IPI (3 mg/kg every 3 weeks for four cycles) and NIVO (1 mg/kg every 3 weeks for four cycles). He had an optimal glycaemic control (HbA1C 6.2% two months before ICI initiation) under oral antidiabetic medication (metformin, sitagliptin and gliclazide) (Table 1). Two weeks after the first ICI infusion, he was admitted to the hospital with vomiting, polyuria, polydipsia, hyperglycaemia (46 mmol/L), severe acidosis (pH 6.9) and presence of ketones bodies in urine (> 7.8 mmol/L) (Table 1). Treatment protocol for DKA with continuous intravenous insulin was initiated with a favourable outcome within 8 hours. Further workup revealed an elevated Glutamic Acid Decarboxylase antibody (GADA) titre 19,770 IU/ml (< 10) consistent with autoimmune T1DM (Table 1). Multiple daily insulin injections were started. Cerebral CT-scan performed 24 hours later showed a progression of cerebral metastases and a subarachnoid haemorrhage. The patient died 3 weeks later due to disease progression.

Discussion

The most striking finding in our two cases is the remarkably short time to onset of autoimmune T1DM with severe DKA following a single infusion of a combination ICI therapy with anti-CTLA-4 and anti-PD-1. ICI-induced T1DM is specific to anti-PD-1/PD-L1 use [9–27] as PD-L1 is expressed in β-cells, and PD-1 receptor is expressed by T cells. The interaction PD-1/PD-L1 use [9–27] as PD-L1 is expressed in β-cells, and PD-1 receptor is expressed by T cells. The interaction PD-1/PD-L1 inhibits the activation of autoreactive T-cells, thereby protecting against autoimmune diabetes [28]. Non-obese diabetic (NOD) mice deficient in PD-1 rapidly develop autoimmune diabetes [29]. Injection of anti-PD-1 or anti-PD-L1 in NOD mice caused the development of diabetes with extensive destructive insulitis mediated by specific CD8 T cells [30]. In clinical settings, the occurrence of T1DM under ICI combination therapy has been rarely reported [9–11, 31]. It is characterised by an earlier onset compared to T1DM induced by single-agent anti-PD-1/PD-L1 therapy. Rapid onset T1DM occurring within two to 5 weeks after a single infusion of ICI combination, as observed in our cases is very peculiar. To our knowledge, the largest reported case series of ICI-induced T1DM included twenty-seven patients: twenty-two of them were on anti-PD-1 or anti-PD-L1 alone, and only five were on IPI-NIVO combination. Among these five patients, only one presented T1DM following a single exposition to IPI-NIVO and was diagnosed within 5 weeks. In the aforementioned case series, the median time to onset was 20 weeks, and most cases associated with single-agent anti-PD-1/PD-L1 therapy occurred after 10 weeks [8]. The unexpected acute onset of autoimmune T1DM observed in our cases, especially the first one, could be explained by an extensive acute insulitis as reflected by the unusual remarkably elevated GADA titres, which were ten to forty-fold higher than
those reported in the literature [32]. GADA, which is a critical marker of autoimmune T1DM, is usually detected in 30 to 50% of ICI-induced diabetes cases [8, 12, 33]. Correlation between GADA positivity and a shorter time to onset of diabetes was demonstrated in a recent study involving twenty-four patients treated with anti-PD-1 [34]. The median time to onset under anti-PD-1 treatment was 3 weeks in GADA-positive individuals vs 12.5 weeks in GADA negative individuals. Moreover, higher GADA titres may be linked to the earlier onset and greater clinical severity of diabetes in patients who presented a fulminant T1DM occurring either spontaneously or under anti-PD-1 treatment [35]. Presence of β-cell autoantibodies before ICI initiation could be a risk factor of diabetes occurrence. However, this parameter was poorly assessed in the literature and was not tested in our patients since it is not recommended in routine clinical practice [36, 37]. It is noteworthy that nearly 50% of anti-PD-1/PD-L1-induced inaugural DKA cases are GADA negative, but they also require long-term insulin therapy like the classic autoimmune T1DM [38, 39]. GADA-negative T1DM under anti-PD-1 therapy could be triggered by a sudden and major activation of beta-cell reactive CD8+ T-cell clones without the involvement of humoral immunity in the short time frame before overt diabetes [39].

The presence of pre-existing T2DM such as in case 1 does not preclude the onset of ICI-induced T1DM. Autoimmune diabetes superimposed on T2DM in the setting of ICI is extremely rare with only two cases being

| Case n° 1 | Case n° 2 | Changizzadeh et al. [9] | Gunawan et al. [10] | Lowe et al. [11] |
|-----------|-----------|-------------------------|---------------------|------------------|
| Age (years) / Gender | 60/M | 80/F | 42/M | 52/M | 54/M |
| History of diabetes | T2DM | No | No | No | No |
| Familial history of diabetes | No | No | No | NR | NR |
| Neoplasia | Melanoma stage IV | Melanoma stage IV | Melanoma stage IV | Melanoma stage IV | |
| Prior corticosteroid administration | No | No | No | Yesa | Yesb |
| ICI regimen | IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks | IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks | IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks | IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks | |
| Time to T1DM onset | 2 weeks (1 cycle) | 5 weeks (1 cycle) | 12 weeks (3 cycles) | 11 weeks (3 cycles) | 19 weeks (3 cycles) |
| DKA | Yes | Yes | Yes | No | Yes |
| Plasma glucose (mmol/L) | 46 | 48.4 | 40.4 | 20.8 | NR |
| Ketones bodies (mmol/L) | | | | | |
| Plasma | NA | NA | NR | 2.4 | NR |
| Urine | > 7.8 | > 7.8 | NR | NR | 0.40 |
| HbA1C (%) | 7.5 | NA | 6.5 | 7.7 | NR |
| C-Peptide (nmol/L) | NA | NA | NR | 0.05 (N: 0.4–1.5) | NR |
| T1DM-related autoantibodies | + (GADA, ICA, IA2) | + (GADA, ICA) IA2 | - (GADA, IA2, ZnT8A) | - (GADA, IA2, ZnT8A) | (GADA) |
| Other immune-related endocrine toxicities | None | Autoimmune thyroiditis | None | Hypophysitis, Diabetes insipidus | Autoimmune thyroiditis |
| Non endocrine immune related toxicities | Presumed immune-checkpoint inhibitor-induced pancreatic injury | None | Colitis | None | Hepatitis, Colitis |
| Definitive discontinuation of ICI | Yes | Yes | Yes | Yes | Yes |

*aIndication: autoimmune hypophysitis; Dexamethasone 8 mg twice a day for 24 h and then hydrocortisone 30 mg/day were started five weeks before T1DM onset.

bIndication: autoimmune hepatitis and colitis; Prednisone was started ten weeks before T1DM and discontinued before T1DM onset. Abbreviations: M Male, F Female, ICI Immune checkpoint inhibitors, IPI Ipilimumab, NIVO Nivolumab, W Week, T2DM Type 2 diabetes mellitus, T1DM Type 1 diabetes mellitus, NA Not analysed, NR Not reported.
reported so far in the setting of ICI combination therapy with relatively early onset (three and 4 weeks after ICI initiation respectively) [32].

Regarding associated factors, other irAE can occur in up to 70% of patients before or concurrently with ICI-induced diabetes. Thyroiditis with transient thyrotoxicosis is the most frequent irAE with a prevalence rate ranging from 23 to 40% in ICI-induced T1DM patients [8, 12, 14, 17]. Immune-checkpoint inhibitor-induced pancreatic injury was reported in nearly 30% of patients on the day of ICI-induced diabetes diagnosis [8]. Genetic susceptibility for ICI-induced diabetes including potential predisposing HLA genotypes is still a matter of debate [8, 11, 14, 17–20, 22, 24]. Accordingly, HLA types were not routinely assessed in our cases.

Clinical practice issues
ICI-induced T1DM is a medical emergency since severe inaugural DKA occurs in 60 to 85% of cases [12]. This condition can be particularly life-threatening in these frail cancer patients who are older than the majority of classic T1DM patients [8]. As for classic T1DM, ICI-induced diabetes is also caused by a severe insulin deficiency with low or undetectable levels of C-peptide [12] and require long-term insulin therapy. The diagnosis can be initially challenging because of the very rapid onset of hyperglycaemia even after the first ICI administration. Typical symptoms such as polyuria and polydipsia can thus be missing as in our second case, and HbA1C can be relatively low as observed in our first case [9–11]. Moreover, patients may present with non-specific complaints that can be linked to either cancer complications as observed in our second case or gastrointestinal toxicity, which occurs more frequently than diabetes [8–10].

According to current guidelines, fasting venous blood glucose should be tested only in patients receiving anti-PD-1/PD-L1 therapy, with close monitoring especially during the first 6 months, which is the highest risk period for endocrine toxicity onset [37]. In our opinion, patient education for rapid recognition of DKA symptoms and urgent medical referral is more useful than serial monitoring of glucose levels since ICI-induced DKA can occur within a very short time frame. For patients with pre-existing diabetes and treated with anti-PD-1/PD-L1, self-monitoring of blood glucose should be proposed or reinforced [37]. If ICI-induced T1DM occurs, insulin therapy should be immediately started according to standards of care. Assessment of HbA1C and antibody panel (GADA, anti-IA2 and anti-ZnT8 if available), as well as serum insulin and C-peptide whenever it is possible, is useful for phenotyping this rare entity, but not essential. It is also important to evaluate the pituitary function not to overlook a concurrent hypophysitis or adrenalitis that may partially mimic DKA symptoms [11]. ICI should be temporarily stopped until DKA resolution and then be rapidly resumed [26, 37].

Unlike the majority of severe non-endocrine ICI toxicities that are responsive to corticosteroid therapy, ICI-induced T1DM is not reversed by corticosteroids [9–11, 13, 24, 27, 37] and requires long-term insulin therapy. As ICI are used in early oncological disease nowadays, the overall survival could be improved, and thus glycaemic target should be individualised. In patients with limited overall survival due to advanced oncological situation, glycaemic targets should be less stringent, with HbA1C < 8.0% [37], but in other cases, the “standard” HbA1C-goal should be targeted [40].

To conclude, oncological patients treated with combination therapy of anti-PD-1/PD-L1 and anti-CTLA-4 can develop a particular pattern of T1DM, with very rapid onset within a few weeks after starting ICI therapy, even with a pre-existing T2DM. Reporting to pharmacovigilance system is highly recommended to gather clinical information and help to identify better the natural history of this rare but potentially life-threatening adverse event. Assessment of T1DM antibodies at baseline could be useful to offer personalised monitoring for patients at high risk of ICI-induced diabetes. Further studies are warranted to determine predictive markers of ICI-induced T1DM.

Abbreviations
CTLA-4: Cytotoxic T-lymphocyte antigen-4; DKA: Diabetic ketoacidosis; GADA: Glutamic acid decarboxylase antibody; ICI: Immune checkpoint inhibitor; IPT: Ipilimumab; irAE: Immune-related adverse events; Nivo: Nivolumab; NOD: Non-obese diabetic; PD-1: Programmed cell death protein 1; PD-L1: Programmed cell death protein 1 ligand; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus

Acknowledgements
Not applicable

Availability of data and material
Data sharing not applicable to this article as no datasets were generated or analysed for this paper.

Authors’ contributions
MZ wrote the first draft of the paper. CM, LM, HC & NP edited to specific sections. CK & FL edited and wrote the final manuscript. All authors accepted the final version.

Funding
None.

Ethics approval and consent to participate
Ethics approval: Not applicable.
Consent for publication: A written informed consent was obtained from the patient 1 and from next of kin for patient 2 for the publication of the case report. A copy of the written consent is available for review by the Editors.

Competing interests
The authors have no conflict of interest to disclose.

Author details
1 Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital (CHUV), University of Lausanne, Av. de La Sallaz 8, 1011 Lausanne,
Switzerland. *Service of Clinical Pharmacology, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.

Received: 19 August 2019 Accepted: 2 December 2019

Published online: 23 December 2019

References

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

2. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in Advanced melanoma. N Engl J Med. 2015;372(26):2521–32.

3. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.

4. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.

5. Spain L, Deem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:1–60.

6. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56.

7. Barroso-Sousa R, Barry WT, Gardiño-Castro AG, Hodi FS, Min L, Krop E, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. Endocrine dysfunction and immune checkpoint inhibitor Regimens. Endocrine dysfunction and immune checkpoint inhibitor regimens. JAMA Oncol. 2016;2(4):173–82.

8. Starnatoli AM, Quandt Z, Perdigoto AL, Clark PL, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2020;206(3):883.

9. Changizzadeh PN, Mukamkalla SKR, Armenio VA. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma. J Immun Cancer. 2017;5(1):97.

10. Gunawan F, George E, Roberts A. Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies. Endocrinol. Diab Metab Case Rep. 2018;2018(3):0146.

11. Lowe JR, Perry DJ, Salama AKS, Mathews CE, Moss LG, Hanks BA. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immun Cancer. 2016;5(9):13.

12. Clotman K, De Block CEM, Janssens K, Specenier P, Weets I. Programmed cell death-1 inhibitor therapy and insulin-dependent diabetes mellitus secondary to combination ipilimumab and nivolumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.

13. Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diab Care. 2015;38(4):e55

14. Gaudy C, Clévy C, Monestier S, Dubois NC, Pellerin J, Albacker LA, et al. Combination of ipilimumab and nivolumab in a patient with metastatic melanoma. JAMA Oncol. 2016;2(4):173–82.

15. Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes. Diab Care. 2015;38(9):e137.

16. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. Endocrine dysfunction and immune checkpoint inhibitor Regimens. Endocrine dysfunction and immune checkpoint inhibitor regimens. JAMA Oncol. 2016;2(4):173–82.

17. Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes. Diab Care. 2015;38(9):e137.

18. Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015;64(6):765–7.

19. Meltell M, Eaton KD, Brooks-Worrell BM, Hapogian WA, Martins R, Palmer JP, et al. Anti-PD-1 and anti–PD-L1 monoclonal antibodies causing type 1 diabetes. Diab Care. 2015;38(9):e137.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.